STAT March 26, 2024
Hello, everyone. Damian here with a look at a pivotal FDA approval, good news for a small biotech company, and why not all buyouts are worth writing home about.
The need-to-know this morning
- Viking Therapeutics reported results from an early-stage study of its oral obesity drug, showing a 3.3% placebo-adjusted average weight loss after four weeks, with no safety issues. The company plans to advance the medicine into the next phase of development.
Merck’s next big thing is (probably) on the way
At some point today, the FDA is expected to approve a cardiovascular therapy from Merck that analysts have tabbed as the company’s most important drug launch in years.
It’s called sotatercept, and it’s an injectable treatment...
Today's Sponsors
Today's Sponsor